Industry Leader Jonathan Freeman, Ph.D. Appointed at ARTBIO as CBO for Future Growth

In an exciting development within the biotech sector, ARTBIO, Inc., a prominent clinical-stage radiopharmaceutical company, has announced the appointment of Dr. Jonathan Freeman as its new Chief Business Officer (CBO). This strategic move reflects the company's commitment to expanding its operations and enhancing its clinical capabilities, following a successful growth period in 2025.

Dr. Freeman will step into this crucial newly established role to oversee ARTBIO's corporate business development and strategic partnerships. With over 25 years of extensive experience in the healthcare landscape, he is equipped to guide the company through its evolving growth trajectory. As noted by Emanuele Ostuni, CEO of ARTBIO, “The next 18 months will be a vital period of growth as we expand our clinical and manufacturing operations globally.” The insight and expertise Dr. Freeman brings to the management team will certainly be invaluable during this pivotal time.

Before his journey with ARTBIO, Dr. Freeman honed his skills as the co-founder and COO at Anthos Therapeutics, where he contributed to the company’s notable acquisition by Novartis for a staggering $3.1 billion. His background includes significant roles in leading strategy and portfolio groups at Merck KGaA, and he has held important positions at Baxter International and Serono. Notably, Dr. Freeman is also a co-founder of Neurvati Neurosciences and GRIN Therapeutics, boasting involvement with numerous drug approvals and product launches.

Dr. Freeman's educational credentials further enhance his profile, having earned his Ph.D. from Cancer Research UK along with a M.A. (Cantab) and B.A. (Hons) in Biochemistry from the University of Cambridge. His qualifications solidify an already impressive foundation as he embarks on this new role at ARTBIO, a company dedicated to redefining cancer care through innovative alpha radioligand therapies using the 212Pb isotope.

ARTBIO is pioneering a unique approach within this rapidly evolving field, leveraging AlphaDirect™ technology, which sets the stage for a new era of alpha radioligand therapies (ARTs). The company's proactive strategy focuses on selecting optimal isotopes and tumor-specific targets, aiming for therapeutics that prioritize both efficacy and patient safety. Currently, ARTBIO is advancing several pipeline programs, with its leading initiative, AB001, targeting metastatic castration-resistant prostate cancer, actively participating in Phase 1 clinical trials.

The legacy of ARTBIO is rooted in a nearly century-long history of radiation therapy advancements spearheaded by researchers at the University of Oslo and Norway's Radium Hospital. As ARTBIO forges ahead under Dr. Freeman’s stewardship, the company stands poised to capitalize on the growing potential of radiopharmaceuticals, with a steadfast focus on advancing patient outcomes.

Dr. Freeman, reflecting on his new role, expressed enthusiasm: “This is an incredible opportunity for me to join a fast-rising oncology company that is laser-focused on improving patient outcomes. Radiopharmaceuticals hold tremendous promise, and I'm excited to help shape this next chapter for ARTBIO.” His vision and leadership will undoubtedly contribute to the company’s growth as it embarks on the next phase of development within the cancer treatment landscape.

Stay connected with ARTBIO as it continues its mission of innovation and excellence in the field of radiopharmaceuticals. For more insights and updates, visit their official website at www.artbio.com and follow them on LinkedIn.